Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 45 - Medicinal preparations containing active ingredients not provided for in groups
Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
05/2003
05/15/2003WO2002058730A3 Compositions for treatment of ocular neovascularization
05/15/2003WO2002056027A3 Regulation of neutral development by daedalos
05/15/2003WO2002048366A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002048365A3 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof
05/15/2003WO2002040016A8 Association of calpain inhibitors and reactive oxygen species trapping agents
05/15/2003WO2002038181A3 Synergistic medicament containing aromatic agents and having an antagonistic, regenerative and/or protagonist decontamination effect
05/15/2003WO2002030462A9 Hedgehog antagonists, methods and uses related thereto
05/15/2003WO2002029031A3 Isoprenoid-dependent ras anchorage (idra) proteins
05/15/2003WO2001080832A3 Administration of a thiol-based chemoprotectant compound
05/15/2003WO2001071309A3 Methods and reagents for regulation of cellular responses in biological systems
05/15/2003US20030093157 Biocompatible,bulking agent or implant that degrades slowly under biological conditions, is hypoallergenic, non-migratory, relatively inexpensive and simple to apply; for therapy of congenital anomaly, a scar or a wrinkle
05/15/2003US20030092908 Autoimmune diseases; rheumatic diseases; multiple sclerosis; inflammatory bowel disease; immunosuppressants
05/15/2003US20030092891 Expressed ligand - vascular intercellular signalling molecule
05/15/2003US20030092767 Antiinflammatory agents; respiratory system disorders; using enzyme inhibitor
05/15/2003US20030092764 Oxidation resistance
05/15/2003US20030092750 Insulin activation
05/15/2003US20030092745 Combination therapy
05/15/2003US20030092744 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof
05/15/2003US20030092736 Substituted azole acid derivatives useful as antidiabetic and antiobesity agents and method
05/15/2003US20030092735 Use of substance P antagonists for the treatment of chronic fatigue syndrome and/or fibromyalgia and use of NK-1 receptor antagonists for the treatment of chronic fatigue syndrome
05/15/2003US20030092729 Anticancer agents; modulating glycoprotein
05/15/2003US20030092724 Multilayer dosage form
05/15/2003US20030092721 Antiinflammatory agents; rheumatic diseases
05/15/2003US20030092720 Drug efflux pump inhibitor
05/15/2003US20030092719 Methods and kits for treating depression or preventing deterioration of cognitive function
05/15/2003US20030092717 Inhibitors of p38 kinase
05/15/2003US20030092715 Aryl and biaryl compounds having MCH modulatory activity
05/15/2003US20030092707 Treatment of breast cancer
05/15/2003US20030092706 Mixtures of phosphodiesterase inhibitor and antiarthritic agents; bioavailability, side effect reduction
05/15/2003US20030092705 Reverse malaria drug resistance
05/15/2003US20030092697 Antidiabetic, antilipemic agents; cardiovascular disorders; anticancer agents
05/15/2003US20030092690 Administering by inhalation
05/15/2003US20030092675 Skin treatment using a new retinoid
05/15/2003US20030092668 Methods and compositions for reducing ischemic injury of the heart by administering adenosine receptor agonists and antagonists
05/15/2003US20030092645 Cloning, expression, viral and delivery vectors and hosts
05/15/2003US20030092638 Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
05/15/2003US20030092637 Novel compounds
05/15/2003US20030092633 Preventing desensitization of receptors
05/15/2003US20030092631 IGF antagonist peptides
05/15/2003US20030092629 Inhibitors of memapsin 2 and use thereof
05/15/2003US20030092623 Inducing proliferation of endothelial cells; use of Bv8 antagonists to treat testicular cancer and hormone dependent tumors; Bv8 is a small protein originally isolated from the skin secretions of the frog Bombina variegata
05/15/2003US20030092606 Formulations for amylin agonist peptides
05/15/2003US20030092601 Microcompetition and human disease
05/15/2003US20030092163 Probiotic bifidobacterium strains
05/15/2003US20030092084 EBV-infected stomach cancer cell line
05/15/2003US20030092079 Methods for identifying compounds for treatment of cell proliferative disorders associated with adaptor protein interactions
05/15/2003US20030092054 Protein complexes and assays for screening anti-cancer agents
05/15/2003US20030092044 Nucleotide sequences coding polypeptide for use in the treatment of apoptosis, inflammatory and autoimmune disorders
05/15/2003US20030092043 Melanoma differentiation associated gene - 5 and promoter and uses thereof
05/15/2003US20030092011 Human cDNAs and proteins and uses thereof
05/15/2003US20030091974 Detecting compounds capable of exhausting mast cells; culture mast cells, incubate with modulator, measure mast cell death, classify compound
05/15/2003US20030091668 Process and composition for controlling fecal hair excretion and trichobezoar formation
05/15/2003US20030091666 Methods and compositions for treating dermatological disorders with Morinda citrifolia
05/15/2003US20030091654 Dietetics, antidiabetic agents; using chromium complex
05/15/2003US20030091651 Oil homogenized with sterols; protective coating for stomach
05/15/2003US20030091635 Sustained release; reduced tendency to drug abruse
05/15/2003US20030091621 Encapsulated drugs
05/15/2003US20030091613 Mixture of whey protein, carbohydrates, vitamins and minerals
05/15/2003US20030091611 Antiproliferative agents ; antiinflammatory agents; insertable stent
05/15/2003US20030091610 Use of non-digestible polymeric foams to sequester ingested materials thereby inhibiting their absorption by the body
05/15/2003US20030091607 Wrinkle resistance; cosmetics
05/15/2003US20030091594 CD4-independent HIV envelope proteins as vaccines and therapeutics
05/15/2003US20030091582 Autoimmune diseases; antitumor agents; antiallergens
05/15/2003US20030091581 Materials and methods relating to the diagnosis and treatment of pre-eclampsia and diabetes
05/15/2003US20030091574 Combination treatment of pancreatic cancer
05/15/2003US20030091572 Methods and compositions for the treatment and diagnosis of pain disorders using 2047
05/15/2003US20030091571 Methods and compositions for the diagnosis and treatment of hematological disorders using 2777
05/15/2003US20030091570 Analgesics; antiinflammatory agents; analyzing drug as to ability to modulation gene expression
05/15/2003US20030091569 Methods for the treatment of carcinoma
05/15/2003US20030091561 Anticancer agents
05/15/2003US20030091553 Use of histamine to treat liver disease
05/15/2003US20030091540 Uniform spreading into body cavities
05/15/2003US20030091515 Method of treating mucositis
05/15/2003US20030091512 Water stabilized medicinal aerosol formulation
05/15/2003US20030091510 Administering fungicide to mucous membrane
05/15/2003US20030091509 Novel use of pulmonary surfactant for the prophylaxis and treatment of chronic pulmonary diseases
05/15/2003US20030091506 Methods of using 22417, a novel human aminoprotease family member
05/15/2003US20030089369 Pressurised metered dose inhalers (MDI)
05/15/2003CA2466516A1 Targeting the reverse mode of the na+/ca2+ exchanger for the treatment of optic neuropathy associated with glaucoma and ischemic optic neuropathy
05/15/2003CA2466443A1 Selective treatment of il-13 expressing tumors
05/15/2003CA2466336A1 Anti-muscarinic agent and estrogen-agonist for treating unstable or overactive bladder
05/15/2003CA2466232A1 Systems for delivery and release of angiotensin-(1-7)
05/15/2003CA2466138A1 B-cell lymphoma specific antigen for use in diagnosis and treatment of b-cell malignancies
05/15/2003CA2466106A1 Methods of treating endometreosis
05/15/2003CA2466083A1 Compositions for the treatment of infectious diseases
05/15/2003CA2465948A1 A method for treating inflammatory bowel disease
05/15/2003CA2465945A1 Nutritional supplements and methods for prevention, reduction and treatment of radiation injury
05/15/2003CA2465921A1 Novel compositions and methods for cancer
05/15/2003CA2465894A1 Method for treating or preventing inflammatory diseases
05/15/2003CA2465886A1 Methods of promoting uptake and nuclear accumulation of polyamides in eukaryotic cells
05/15/2003CA2465862A1 Methods for monitoring and guiding therapeutic suppression of parathyroid hormone in renal patients having secondary hyperparathyroidism
05/15/2003CA2465731A1 Screening for hepatitis c virus entry inhibitors
05/15/2003CA2465711A1 Aminopyrimidines and pyridines
05/15/2003CA2465700A1 Solid oral compositions
05/15/2003CA2465499A1 Compositions and methods for treating osteoporosis
05/15/2003CA2465364A1 Pharmaceutical composition comprising an adenosine a1/a2 agonist and a sodium hydrogen exchanger inhibitor
05/15/2003CA2465186A1 Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
05/15/2003CA2464765A1 Type 2 cytokine receptor and nucleic acids encoding same
05/15/2003CA2464717A1 Compounds and methods for treating transplant rejection
05/15/2003CA2464531A1 Soluble cd40l(cd154) as a prognostic marker of atherosclerotic diseases
1 ... 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 ... 1151